462 related articles for article (PubMed ID: 19952936)
1. Use of myocardin in the classification of mesenchymal tumors of the uterus.
Liang J; Wu L; Xiao H; Li N; Wang H; Cheng C; Bai R; Zhao Y; Zheng H
Int J Gynecol Pathol; 2010 Jan; 29(1):55-62. PubMed ID: 19952936
[TBL] [Abstract][Full Text] [Related]
2. Use of histone deacetylase 8 (HDAC8), a new marker of smooth muscle differentiation, in the classification of mesenchymal tumors of the uterus.
de Leval L; Waltregny D; Boniver J; Young RH; Castronovo V; Oliva E
Am J Surg Pathol; 2006 Mar; 30(3):319-27. PubMed ID: 16538051
[TBL] [Abstract][Full Text] [Related]
3. Use of oxytocin receptor expression in distinguishing between uterine smooth muscle tumors and endometrial stromal sarcoma.
Loddenkemper C; Mechsner S; Foss HD; Dallenbach FE; Anagnostopoulos I; Ebert AD; Stein H
Am J Surg Pathol; 2003 Nov; 27(11):1458-62. PubMed ID: 14576480
[TBL] [Abstract][Full Text] [Related]
4. [Immunohistochemical study of endometrial stromal sarcoma and smooth-muscle tumors of the uterus].
Farah-Klibi F; Ben Hamouda S; Ben Romdhane S; Sfar R; Koubaa A; Ben Jilani S; Zermani R
J Gynecol Obstet Biol Reprod (Paris); 2008 Sep; 37(5):457-62. PubMed ID: 18565690
[TBL] [Abstract][Full Text] [Related]
5. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases.
Chu PG; Arber DA; Weiss LM; Chang KL
Mod Pathol; 2001 May; 14(5):465-71. PubMed ID: 11353058
[TBL] [Abstract][Full Text] [Related]
6. h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors.
Nucci MR; O'Connell JT; Huettner PC; Cviko A; Sun D; Quade BJ
Am J Surg Pathol; 2001 Apr; 25(4):455-63. PubMed ID: 11257619
[TBL] [Abstract][Full Text] [Related]
7. [Myxoid mesenchymal tumors of uterus: endometrial stromal and smooth muscle tumors, myxoid variant].
Chesnais AL; Watkin E; Beurton D; Devouassoux-Shisheboran M
Ann Pathol; 2011 Jun; 31(3):152-8. PubMed ID: 21736994
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study.
Mikami Y; Hata S; Kiyokawa T; Manabe T
Mod Pathol; 2002 Sep; 15(9):923-30. PubMed ID: 12218209
[TBL] [Abstract][Full Text] [Related]
9. Expression of the O-linked N-acetylglucosamine containing epitope H in normal myometrium and uterine smooth muscle cell tumors.
Sgantzos MN; Galani V; Arvanitis LD; Charchanti A; Psathas P; Nakou M; Havaki S; Kallioras V; Marinos E; Vamvakopoulos NC; Kittas C
Pathol Res Pract; 2007; 203(1):31-7. PubMed ID: 17129677
[TBL] [Abstract][Full Text] [Related]
10. h-Caldesmon, a novel smooth muscle-specific antibody, distinguishes between cellular leiomyoma and endometrial stromal sarcoma.
Rush DS; Tan J; Baergen RN; Soslow RA
Am J Surg Pathol; 2001 Feb; 25(2):253-8. PubMed ID: 11176075
[TBL] [Abstract][Full Text] [Related]
11. Epithelioid smooth muscle tumors of the uterus do not express CD1a: a potential immunohistochemical adjunct in their distinction from uterine perivascular epithelioid cell tumors.
Fadare O; Liang SX
Ann Diagn Pathol; 2008 Dec; 12(6):401-5. PubMed ID: 18995203
[TBL] [Abstract][Full Text] [Related]
12. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies.
Oliva E; Young RH; Amin MB; Clement PB
Am J Surg Pathol; 2002 Apr; 26(4):403-12. PubMed ID: 11914617
[TBL] [Abstract][Full Text] [Related]
13. Cellular mesenchymal tumors of the uterus: a review emphasizing recent observations.
Oliva E
Int J Gynecol Pathol; 2014 Jul; 33(4):374-84. PubMed ID: 24901397
[TBL] [Abstract][Full Text] [Related]
14. IFITM1 Outperforms CD10 in Differentiating Low-grade Endometrial Stromal Sarcomas From Smooth Muscle Neoplasms of the Uterus.
Busca A; Gulavita P; Parra-Herran C; Islam S
Int J Gynecol Pathol; 2018 Jul; 37(4):372-378. PubMed ID: 28700435
[TBL] [Abstract][Full Text] [Related]
15. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system.
D'Angelo E; Spagnoli LG; Prat J
Hum Pathol; 2009 Nov; 40(11):1571-85. PubMed ID: 19540555
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic immunohistochemistry in uterine sarcomas: a study of 397 cases.
Abeler VM; Nenodovic M
Int J Gynecol Pathol; 2011 May; 30(3):236-43. PubMed ID: 21464730
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
18. Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases.
Soslow RA; Ali A; Oliva E
Am J Surg Pathol; 2008 Jul; 32(7):1013-21. PubMed ID: 18469708
[TBL] [Abstract][Full Text] [Related]
19. True smooth muscle tumors of the small intestine: a clinicopathologic, immunhistochemical, and molecular genetic study of 25 cases.
Miettinen M; Sobin LH; Lasota J
Am J Surg Pathol; 2009 Mar; 33(3):430-6. PubMed ID: 18971781
[TBL] [Abstract][Full Text] [Related]
20. "Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas.
Veras E; Zivanovic O; Jacks L; Chiappetta D; Hensley M; Soslow R
Am J Surg Pathol; 2011 Nov; 35(11):1626-37. PubMed ID: 21921786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
